

# Muneaki Shimada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8055582/publications.pdf>

Version: 2024-02-01

43  
papers

891  
citations

586496

16  
h-index

536525

29  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. Archives of Gynecology and Obstetrics, 2023, 307, 525-532.	0.8	5
2	Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. Brachytherapy, 2022, 21, 141-150.	0.2	1
3	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. European Journal of Surgical Oncology, 2022, 48, 1407-1413.	0.5	6
4	Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer Science, 2022, , .	1.7	2
5	Rethinking the significance of surgery for uterine cervical cancer. Journal of Obstetrics and Gynaecology Research, 2022, 48, 576-586.	0.6	3
6	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). Journal of Gynecologic Oncology, 2022, 33, .	1.0	4
7	Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. International Journal of Clinical Oncology, 2022, 27, 1507-1515.	1.0	6
8	Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. International Journal of Clinical Oncology, 2021, 26, 207-215.	1.0	6
9	Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic. European Journal of Cancer, 2021, 148, 117-120.	1.3	9
10	Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. International Journal of Gynecological Cancer, 2021, 31, 991-1000.	1.2	7
11	Clinico-pathological characteristics of patients with stage IB1 to IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan. International Journal of Clinical Oncology, 2021, 26, 1541-1552.	1.0	4
12	Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer. Toxins, 2021, 13, 461.	1.5	14
13	A simple technique of vaginal cuff closure to prevent tumor cell spillage in laparoscopic radical hysterectomy for uterine cervical cancer. Asian Journal of Endoscopic Surgery, 2021, 14, 665-668.	0.4	5
14	The Impact of Histological Subtype on Survival Outcome of Patients with Stage IIB-IVA Cervical Cancer Who Received Definitive Radiotherapy. Tohoku Journal of Experimental Medicine, 2021, 255, 303-313.	0.5	11
15	Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer. Cancers, 2020, 12, 1705.	1.7	2
16	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. Current Oncology Reports, 2020, 22, 28.	1.8	11
17	Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer. Tohoku Journal of Experimental Medicine, 2020, 252, 339-351.	0.5	7
18	Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study. Journal of Clinical Medicine, 2019, 8, 1822.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival. <i>Journal of Clinical Medicine</i> , 2019, 8, 156.	1.0	12
20	Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1417-1424.	0.5	10
21	Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2019, 133, 1086-1098.	1.2	77
22	Comparison of laparoscopic surgery and conventional laparotomy for surgical staging of patients with presumed low-risk endometrial cancer: The current state of Japan. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 99-104.	0.5	24
23	Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e103.	1.0	19
24	Left fallopian tube prolapse after abdominal radical trachelectomy treated by laparoscopic left salpingectomy: A case report. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 372-376.	0.0	0
25	Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 99-106.	1.2	63
26	Identifying a candidate population for ovarian conservation in young women with clinical stage IB–IIB cervical cancer. <i>International Journal of Cancer</i> , 2018, 142, 1022-1032.	2.3	28
27	Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB–IIB cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e11.	1.0	34
28	Comparison of adjuvant therapy for node–positive clinical stage IB–IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. <i>International Journal of Cancer</i> , 2017, 141, 1042-1051.	2.3	59
29	Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. <i>Medical Oncology</i> , 2017, 34, 134.	1.2	16
30	Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies. <i>Current Oncology Reports</i> , 2017, 19, 25.	1.8	3
31	A case of asymptomatic peritoneal endosalpingiosis after laparoscopic myomectomy. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2017, 33, 168-172.	0.0	0
32	Ovarian conservation for young women with clinical stage IB–IIB cervical cancer in Japan. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e60.	1.0	8
33	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. <i>Oncotarget</i> , 2017, 8, 106866-106875.	0.8	30
34	Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1128-1135.	1.0	22
35	Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 561-567.	1.2	9
36	Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. <i>International Journal of Clinical Oncology</i> , 2015, 20, 556-560.	1.0	41

#	ARTICLE	IF	CITATIONS
37	Cytoplasmic Maspin Expression Correlates with Poor Prognosis of Patients with Adenocarcinoma of the Uterine Cervix. <i>Yonago Acta Medica</i> , 2015, 58, 151-6.	0.3	8
38	Outcome of stage IB2â€“IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. <i>International Journal of Clinical Oncology</i> , 2014, 19, 348-353.	1.0	17
39	Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1333-1340.	1.2	42
40	Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. <i>Molecular and Clinical Oncology</i> , 2013, 1, 780-784.	0.4	52
41	Ovarian metastasis in carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 101, 234-237.	0.6	188
42	Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer. <i>Gynecologic Oncology</i> , 2004, 93, 628-631.	0.6	19
43	An Evaluation of Heparinized Syringes with Low-dose Heparin. <i>Ika Kikaigaku</i> , 1990, 60, 217-220.	0.0	1